Concentration of vascular endothelial growth factor in patients with acute coronary syndrome

Cytokine

Volumn 61, Issue 2, 2013, Pages 664-669

  Konopka, Anna ^a   Janas, Jadwiga ^a   Piotrowski, Walerian ^a   Stepińska, Janina ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Acute coronary syndrome; Biomarkers; NSTEMI; STEMI; VEGF

Indexed keywords

C REACTIVE PROTEIN; TRIACYLGLYCEROL; TROPONIN I; VASCULOTROPIN;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HEART MUSCLE INJURY; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ACUTE CORONARY SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873208224     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.12.001     Document Type: Article

References (56)

1. Folkman J. Angiogenesis in cancer, vascular rheumatoid and other disease. Nature Med 1995, 1:27-31.
2. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996, 32A:2413-2422.
3. Banai S., Jaklitsch M.T., Shou M., Lazarous D.F., Scheinowitz M., Biro S., et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994, 89:2183-2189.
4. Pearlman J.D., Hibberd M.G., Chuang M.L., Harada K., Lopez J.J., Gladstone S.R., et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nature Med 1995, 1:1085-1089.
5. Harada K., Friedman M., Lopez J.J., Wang S.Y., Li J., Prasad P.V., et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996, 270:H1791-H1802.
6. Yanagisawa-Miwa A., Uchida Y., Nakamura F., Tomaru T., Kido H., Kamijo T., et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992, 257:1401-1403.
7. Lazarous D.F., Shou M., Scheinowitz M., Hodge E., Thirumurti V., Kitsiou A.N., et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996, 94:1074-1082.
8. Brown L.F., Yeo K.-T., Berse B., Yeo T.-K., Senger D.R., Dvorak H.F., et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992, 176:1375-1379.
9. Ferrara N., Houck K.A., Jakeman L.B., Winer J., Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992, 13:18-32.
10. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306e-1309e.
11. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
12. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
13. Kimura K., Hashiguchi T., Deguchi T., Horinouchi S., Uto T., Oku H., et al. Serum VEGF - as a prognostic factor of atherosclerosis. Atherosclerosis 2007, 194:182-188.
14. Webb N.J., Bottomley M.J., Watson C.J., Brenchley P.E. Vascular endothelial growth factor (VEGF) is released from platelets during blood clothing: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci 1998, 94:395-404.
15. Kusumanto Y.H., Dam W.A., Hospers G.A.P., Meijer C., Mulder N.H., et al. Platelets and granulocytes, in particular neutrophils form important compartments for circulating vascular endothelial growth factor. Angiogensis 2003, 6:283-287.
16. Verheul H.M.W., Hoekman K., Luykx-de Bakker S., Eekman C.A., Folman C.C., Broxterman H.J., et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997, 3:2187-2190.
17. Banks R.E., Forbes M.A., Kinsey S.E., Stanley A., Ingham E., Walters C., et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998, 77:956-964.
18. Wyrendaele W., Derua R., Hoylaert M.F., Pawinski A., Waelkens E., de Bruijn E.A., et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?. Ann Oncol 1999, 10:965-971.
19. Salven P., Orpana A., Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999, 5:487-491.
20. Möhle R., Green D., Moore M.A.S., Nahman R.L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997, 94:663-668.
21. Gaudry M., Bregerie O., Andrieu V., El Benna J., Pocidalo M.-A., Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood 1997, 90:4153-4161.
22. Scapini P., Calzetti F., Cassatella M.A. On the detection of neutrophil-derived vascular endothelial growth factor (VEGF). J Immunol Methods 1999, 232:121-129.
23. Maulik N. Reactive oxygen species drives myocardial angiogenesis?. Antioxid Redox Signal 2006, 8:2161-2168.
24. Losordo D.W., Vale P.R., Symes J.F., Dunnington Ch.H., Esakof D.D., Maysky M., et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998, 98:2800-2804.
25. Felmeden D.C., Spencer C.G.C., Chung N.A.Y., Belgore F.M., Blann A.D., Beevers D.G., et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the anglo-scandinavian cardiac outcomes trial [ASCOT ]). Am J Cardiol 2003, 92:400-405.
26. Lip P.L., Belgore F., Blann A.D., Hope-Ross M.W., Gibson J.M., Lip G.Y. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci 2000, 41:2115e-2119e.
27. Blann A.D., Belgore F.M., McCollum C.N., Silverman S., Lip P.L., Lip G.Y. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci 2002, 102:187e-194e.
28. Hovind P., Tarnow L., Oestergaard P.B., Parving H.H. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl 2000, 75:S56-S61.
29. Alber H.F., Frick M., Dulak J., Dörler J., Zwick R.-H., Dichtl W., et al. Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. Heart 2005, 91:365-366.
30. Fleisch M., Billinger M., Eberli F.R., Garachemani A.R., Meier B., Seiler Ch. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation 1990, 100:1945-1950.
31. Kucukardali Y., Aydogdu S., Ozmen N., Yonem A., Solmazgul E., Ozyurt M., et al. The relationship between severity of coronary artery disease and plasma level of vascular endothelial growth factor. Cardiovasc Revasc Med 2008, 9:66-70.
32. Seko Y., Imali Y., Suzuki S., Kamijukkoku S., Hayasaki K., Sakomura Y., et al. Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. Clin Sci 1997, 92:453-454.
33. Hojo Y., Ikeda U., Zhu Y., Okada M., Ueno S., Arakawa H., et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. JACC 2000, 35:968-973.
34. Lin T.H., Yen H.W., Su H.M., Chien W.T., Lu Y.H., Voon W.C., et al. Effects of total coronary artery occlusion on vascular endothelial growth factor and transforming growth factor beta. Kaoshiung J Med Sci 2005, 21:460-465.
35. Stewart D.J., Hilton J.D., Arnold J.M., Gregoire J., Rivard A., Archer S.L., et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006, 13:1503-1511.
36. Herrmann J., Best P.J., Ritman E.L., Holmes D.R., Lerman L.O., Lerman A. Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Am Coll Cardiol 2002, 39:1555-1561.
37. Kwon H.M., Sangiorgi G., Ritman E.L., McKena C., Holmes D.R., Schwartz R.S., et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998, 101:1551-1556.
38. Xi L., Ghosh S., Wang X., Das A., Anderson F.P., Kukreja R.C. Hypercholesterolemia enhances tolerance to lethal systemic hypoxia in middle-aged mice. Possible role of VEGF downregulation in brain. Mol Cell Bioch 2006, 291:205-211.
39. Hoffman M., Blum A., Baruch R., Kaplan E., Benjamin M. Leukocytes and coronary heart disease. Atherosclerosis 2004, 172:1-6.
40. Coller B.S. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?. Arterioscler Thromb Vasc Biol 2005, 25:658-670.
41. Dragu R., Huri S., Zuckerman R., Suleiman M., Mutlak D., Agmon Y., et al. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis 2008, 196:405-412.
42. Nijm J., Wikby A., Tompa A., Olsson A.G., Jonasson L. Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol 2005, 95:452-456.
43. Avanzas P., Arroyo-Espliguero R., Cosin-Sales J., Quites J., Zouridakis E., Kaski J.C. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis 2004, 175:151-157.
44. Avanzas P., Arroyo-Espliguero R., Cosin-Sales J., Aldama G., Pizzi C., Quiles J., et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 2004, 90:847-852.
45. Mehta J., Dinerman J., Mehta P., Saldeen T.G., Lawson D., Donnelly W.H., et al. Neutrophil function in ischemic heart disease. Circulation 1989, 79:549-556.
46. Mazzone A., De Servi S., Ricevuti G., Mazzucchelli I., Fossati G., Pasotti D., et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993, 88:358-363.
47. De Servi S., Mazzone A., Ricevuti G., Mazzucchelli I., Fossati G., Gritti D., et al. Clinical and angiographic correlates of leukocyte activation in unstable angina. J Am Coll Cardiol 1995, 26:1146-1150.
48. Takeshita S., Isshiki T., Ochiai M., Ishikawa T., Nishiyama Y., Fusano T., et al. Systemic inflammatory responses in acute coronary syndrome: increased activity observed in polymorphonuclear leukocytes but not T lymphocytes. Atherosclerosis 1997, 135:187-192.
49. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., Maser A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002, 347:5-12.
50. Kristal B., Shurtz-Swirski R., Chezar J., Manaster J., Levy R., Shapiro G., et al. Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens 1998, 11:921-928.
51. Shurtz-Swirski R., Sela S., Herskovits A.T., Shasha S.M., Shapiro G., Nasser L., et al. Involvement of peripheral polymorphonuclear leukocytes in oxidative stress and inflammation in type 2 diabetic patients. Diab Care 2001, 24:104-110.
52. Sela S., Shurtz-Swirski R., Awad J., Shapiro G., Nasser L., Shasha S.M., et al. The involvement of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation among cigarette smokers. Isr Med Assoc J 2002, 4:1015-1019.
53. Sela S., Shurtz-Swirski R., Cohen-Mazor M., Mazor R., Chezar J., Shapiro G., et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 2005, 16:2431-2438.
54. Mazor R., Shurtz-Swirski R., Farah R., Kristal B., Shapiro G., Dorlechter F., et al. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis 2008, 197:937-943.
55. Nijhuis J., Rensen S.S., Slaats Y., van Dielen F.M.H., Buurman W.A., Greve J.W.M. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity 2009, 17:2014-2018.
56. Jacobi J., Sela S., Cohen H.I., Chezar J., Kristal B. Priming of polymorphonuclear leukocytes: a culprit in the initiation of endothelial cell injury. Am J Physiol Heart Circ Physiol 2006, 290:H2051-H2058.